COVID-19 shots in the US are provided by Pfizer (NYSE:PFE)/BioNTech (NASDAQ:BNTX), Moderna (NASDAQ:MRNA) and Novavax (NASDAQ:NVAX).

Novavax (NVAX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced progress in Q4 2024 advancing its corporate growth strategy through ...

In this article, we are going to take a look at where Novavax, Inc. (NYSE:NVAX) stands against other under-the-radar stocks. Investing in under-the-radar stocks can be a savvy move for those ...

Novavax shares are trading lower by 9.8% during Monday's session. Shares of vaccine stocks are trading lower after Moderna issued 2025 revenue guidance below analyst estimates. Next: Access Our ...

Novavax stock (NVAX) skyrocketed Friday ... While Novavax's vaccine did finally reach the market in mid-2022, targeting the booster market, it continued to struggle with $1.7 billion in ...

In trading on Tuesday, shares of Novavax, Inc. (Symbol: NVAX) crossed above their 200 day moving average of $10.66, changing hands as high as $11.55 per share. Novavax, Inc. shares are currently ...